Absolute 0 8 0 8 B-clinical_variable
neutrophil 9 19 9 19 I-clinical_variable
count 20 25 20 25 I-clinical_variable
( 26 27 26 27 I-clinical_variable
ANC 27 30 27 30 I-clinical_variable
) 30 31 30 31 I-clinical_variable
> 32 33 32 33 O
1500 33 37 33 37 B-lower_bound
/ 37 38 37 38 I-lower_bound
mm3 38 41 38 41 I-lower_bound

Advanced 0 8 42 50 O
or 9 11 51 53 O
metastatic 12 22 54 64 B-cancer
esophageal 23 33 65 75 I-cancer
and/or 34 40 76 82 O
gastric 41 48 83 90 B-cancer
cancer 49 55 91 97 I-cancer
( 56 57 98 99 O
15 57 59 99 101 B-lower_bound
- 59 60 101 102 O
30 60 62 102 104 B-upper_bound
enrollment 63 73 105 115 I-upper_bound
slots 74 79 116 121 I-upper_bound
) 79 80 121 122 O

All 0 3 123 126 O
tumors 4 10 127 133 B-cancer
must 11 15 134 138 O
test 16 20 139 143 O
positive 21 29 144 152 O
for 30 33 153 156 O
Rb 34 36 157 159 O
expression 37 47 160 170 O

Any 0 3 171 174 O
tumor 4 9 175 180 B-cancer
type 10 14 181 185 O
if 15 17 186 188 O
tissue 18 24 189 195 O
tests 25 30 196 201 O
positive 31 39 202 210 O
for 40 43 211 214 O
CCND1 44 49 215 220 O
amplification 50 63 221 234 O
, 63 64 234 235 O
CDK4/6 65 71 236 242 O
mutation 72 80 243 251 O
, 80 81 251 252 O
CCND2 82 87 253 258 O
amplification 88 101 259 272 O
OR 102 104 273 275 O
any 105 108 276 279 O
other 109 114 280 285 O
functional 115 125 286 296 O
alteration 126 136 297 307 O
at 137 139 308 310 O
the 140 143 311 314 O
G1 144 146 315 317 O
/ 146 147 317 318 O
S 147 148 318 319 O
checkpoint 149 159 320 330 O

Any 0 3 331 334 O
tumor 4 9 335 340 B-cancer
type 10 14 341 345 O
if 15 17 346 348 O
tissue 18 24 349 355 O
tests 25 30 356 361 O
positive 31 39 362 370 O
for 40 43 371 374 O
CCND1 44 49 375 380 O
amplification 50 63 381 394 O
, 63 64 394 395 O
CDK4/6 65 71 396 402 O
mutation 72 80 403 411 O
, 80 81 411 412 O
CCND2 82 87 413 418 O
amplification 88 101 419 432 O
OR 102 104 433 435 O
any 105 108 436 439 O
other 109 114 440 445 O
functional 115 125 446 456 O
alteration 126 136 457 467 O
at 137 139 468 470 O
the 140 143 471 474 O
G1 144 146 475 477 O
/ 146 147 477 478 O
S 147 148 478 479 O
checkpoint 149 159 480 490 O
. 159 160 490 491 O
( 161 162 492 493 O
15 162 164 493 495 O
- 164 165 495 496 O
30 165 167 496 498 O
enrollment 168 178 499 509 O
slots 179 184 510 515 O
) 184 185 515 516 O

Bilirubin 0 9 517 526 B-clinical_variable
≤ 10 11 527 528 O
1.5 12 15 529 532 B-upper_bound
x 16 17 533 534 I-upper_bound
the 18 21 535 538 I-upper_bound
upper 22 27 539 544 I-upper_bound
limit 28 33 545 550 I-upper_bound
of 34 36 551 553 I-upper_bound
normal 37 43 554 560 I-upper_bound
( 44 45 561 562 I-upper_bound
ULN 45 48 562 565 I-upper_bound
) 48 49 565 566 I-upper_bound

Cisplatin 0 9 567 576 B-cancer
- 9 10 576 577 I-cancer
refractory 10 20 577 587 I-cancer
, 20 21 587 588 O
unresectable 22 34 589 601 O
germ 35 39 602 606 B-cancer
cell 40 44 607 611 I-cancer
tumors 45 51 612 618 I-cancer
( 52 53 619 620 O
15 53 55 620 622 B-lower_bound
- 55 56 622 623 O
30 56 58 623 625 B-upper_bound
enrollment 59 69 626 636 O
slots 70 75 637 642 O
) 75 76 642 643 O

ER 0 2 644 646 B-cancer
positive 3 11 647 655 I-cancer
metastatic 12 22 656 666 I-cancer
breast 23 29 667 673 I-cancer
tumors 30 36 674 680 I-cancer
( 37 38 681 682 O
data 38 42 682 686 O
now 43 46 687 690 O
shows 47 52 691 696 O
all 53 56 697 700 O
to 57 59 701 703 O
be 60 62 704 706 O
Rb 63 65 707 709 O
positive 66 74 710 718 O
. 74 75 718 719 O
) 75 76 719 720 O

Female 0 6 721 727 B-gender
subjects 7 15 728 736 I-gender
of 16 18 737 739 O
childbearing 19 31 740 752 O
potential 32 41 753 762 O
must 42 46 763 767 O
have 47 51 768 772 O
a 52 53 773 774 O
negative 54 62 775 783 B-pregnancy
pregnancy 63 72 784 793 I-pregnancy
test 73 77 794 798 O
at 78 80 799 801 O
screening 81 90 802 811 O

Females 0 7 812 819 B-gender
of 8 10 820 822 O
childbearing 11 23 823 835 O
potential 24 33 836 845 O
are 34 37 846 849 O
defined 38 45 850 857 O
as 46 48 858 860 O
sexually 49 57 861 869 O
mature 58 64 870 876 O
women 65 70 877 882 B-gender
without 71 78 883 890 O
prior 79 84 891 896 B-treatment
hysterectomy 85 97 897 909 I-treatment
or 98 100 910 912 O
who 101 104 913 916 O
have 105 109 917 921 O
had 110 113 922 925 O
any 114 117 926 929 O
evidence 118 126 930 938 O
of 127 129 939 941 O
menses 130 136 942 948 O
in 137 139 949 951 O
the 140 143 952 955 O
past 144 148 956 960 B-upper_bound
12 149 151 961 963 I-upper_bound
months 152 158 964 970 I-upper_bound

For 0 3 971 974 O
subjects 4 12 975 983 O
with 13 17 984 988 O
liver 18 23 989 994 B-cancer
metastases 24 34 995 1005 I-cancer
: 34 35 1005 1006 O
alanine 36 43 1007 1014 B-clinical_variable
aminotransferase 44 60 1015 1031 I-clinical_variable
( 61 62 1032 1033 I-clinical_variable
ALT 62 65 1033 1036 I-clinical_variable
) 65 66 1036 1037 I-clinical_variable
and 67 70 1038 1041 O
aspartate 71 80 1042 1051 B-clinical_variable
aminotransferase 81 97 1052 1068 I-clinical_variable
≤ 98 99 1069 1070 O
5 100 101 1071 1072 B-upper_bound
x 102 103 1073 1074 I-upper_bound
ULN 104 107 1075 1078 I-upper_bound

For 0 3 1079 1082 O
subjects 4 12 1083 1091 O
without 13 20 1092 1099 O
liver 21 26 1100 1105 B-cancer
metastases 27 37 1106 1116 I-cancer
: 37 38 1116 1117 O
alanine 39 46 1118 1125 B-clinical_variable
aminotransferase 47 63 1126 1142 I-clinical_variable
( 64 65 1143 1144 I-clinical_variable
ALT 65 68 1144 1147 I-clinical_variable
) 68 69 1147 1148 I-clinical_variable
and 70 73 1149 1152 O
aspartate 74 83 1153 1162 B-clinical_variable
aminotransferase 84 100 1163 1179 I-clinical_variable
( 101 102 1180 1181 I-clinical_variable
AST 102 105 1181 1184 I-clinical_variable
) 105 106 1184 1185 I-clinical_variable
≤ 107 108 1186 1187 O
2.5 109 112 1188 1191 B-upper_bound
x 113 114 1192 1193 I-upper_bound
ULN 115 118 1194 1197 I-upper_bound

Hemoglobin 0 10 1198 1208 B-clinical_variable
> 11 12 1209 1210 O
9 13 14 1211 1212 B-lower_bound
g 15 16 1213 1214 I-lower_bound
/ 16 17 1214 1215 I-lower_bound
dL 17 19 1215 1217 I-lower_bound

Metastatic 0 10 1218 1228 B-cancer
breast 11 17 1229 1235 I-cancer
cancer 18 24 1236 1242 I-cancer
( 25 26 1243 1244 O
7 26 27 1244 1245 O
triple 28 34 1246 1252 O
negative 35 43 1253 1261 O
, 43 44 1261 1262 O
23 45 47 1263 1265 O
ER+ 48 51 1266 1269 B-clinical_variable
after 52 57 1270 1275 O
the 58 61 1276 1279 O
first 62 67 1280 1285 O
15 68 70 1286 1288 O
patients 71 79 1289 1297 O
are 80 83 1298 1301 O
enrolled 84 92 1302 1310 O
on 93 95 1311 1313 O
the 96 99 1314 1317 O
non 100 103 1318 1321 O
- 103 104 1321 1322 O
CCND1cohort 104 115 1322 1333 B-clinical_variable
; 115 116 1333 1334 O
in 117 119 1335 1337 O
addition 120 128 1338 1346 O
10 129 131 1347 1349 O
HER2 132 136 1350 1354 B-clinical_variable
+ 136 137 1354 1355 I-clinical_variable
for 138 141 1356 1359 O
combination 142 153 1360 1371 O
trastuzumab 154 165 1372 1383 B-treatment
and 166 169 1384 1387 O
PD0332991 170 179 1388 1397 B-treatment
therapy 180 187 1398 1405 I-treatment
) 187 188 1405 1406 O
up 189 191 1407 1409 O
to 192 194 1410 1412 O
55 195 197 1413 1415 B-upper_bound
total 198 203 1416 1421 O
enrollment 204 214 1422 1432 O
slots 215 220 1433 1438 O
B 221 222 1439 1440 O

Metastatic 0 10 1441 1451 B-cancer
colorectal 11 21 1452 1462 I-cancer
cancer 22 28 1463 1469 I-cancer
that 29 33 1470 1474 O
harbors 34 41 1475 1482 O
the 42 45 1483 1486 O
Kras 46 50 1487 1491 B-cancer
or 51 53 1492 1494 O
BRAF 54 58 1495 1499 B-cancer
mutation 59 67 1500 1508 I-cancer
( 68 69 1509 1510 O
15 69 71 1510 1512 O
- 71 72 1512 1513 O
30 72 74 1513 1515 O
enrollment 75 85 1516 1526 O
slots 86 91 1527 1532 O
) 91 92 1532 1533 O

Patients 0 8 1534 1542 O
with 9 13 1543 1547 O
HER2 14 18 1548 1552 B-cancer
- 18 19 1552 1553 O
overexpressing 19 33 1553 1567 O
tumors 34 40 1568 1574 B-cancer
may 41 44 1575 1578 O
receive 45 52 1579 1586 O
trastuzumab 53 64 1587 1598 B-treatment
up 65 67 1599 1601 O
to 68 70 1602 1604 O
the 71 74 1605 1608 O
date 75 79 1609 1613 O
of 80 82 1614 1616 O
starting 83 91 1617 1625 O
therapy 92 99 1626 1633 B-treatment
, 99 100 1633 1634 O
and 101 104 1635 1638 O
may 105 108 1639 1642 O
continue 109 117 1643 1651 O
to 118 120 1652 1654 O
receive 121 128 1655 1662 O
trastuzumab 129 140 1663 1674 O
while 141 146 1675 1680 O
receiving 147 156 1681 1690 O
PD0332991 157 166 1691 1700 B-treatment

Platelets 0 9 1701 1710 B-clinical_variable
> 10 11 1711 1712 O
100,000 11 18 1712 1719 B-lower_bound
/ 18 19 1719 1720 I-lower_bound
mm3 19 22 1720 1723 I-lower_bound

Serum 0 5 1724 1729 B-clinical_variable
creatinine 6 16 1730 1740 I-clinical_variable
≤ 17 18 1741 1742 O
1.5 19 22 1743 1746 B-upper_bound
x 23 24 1747 1748 I-upper_bound
UNL 25 28 1749 1752 B-clinical_variable
or 29 31 1753 1755 O
calculated 32 42 1756 1766 O
creatinine 43 53 1767 1777 B-clinical_variable
clearance 54 63 1778 1787 I-clinical_variable
≥ 64 65 1788 1789 O
60 66 68 1790 1792 B-lower_bound
mL 69 71 1793 1795 I-lower_bound
/ 71 72 1795 1796 I-lower_bound
min 72 75 1796 1799 I-lower_bound

Sexually 0 8 1800 1808 O
active 9 15 1809 1815 O
subjects 16 24 1816 1824 O
( 25 26 1825 1826 O
male 26 30 1826 1830 B-gender
and 31 34 1831 1834 I-gender
female 35 41 1835 1841 I-gender
) 41 42 1841 1842 O
must 43 47 1843 1847 O
use 48 51 1848 1851 B-contraception_consent
accepted 52 60 1852 1860 I-contraception_consent
methods 61 68 1861 1868 I-contraception_consent
of 69 71 1869 1871 I-contraception_consent
contraception 72 85 1872 1885 I-contraception_consent
during 86 92 1886 1892 O
the 93 96 1893 1896 O
course 97 103 1897 1903 O
of 104 106 1904 1906 O
the 107 110 1907 1910 O
study 111 116 1911 1916 O
and 117 120 1917 1920 O
for 121 124 1921 1924 O
3 125 126 1925 1926 B-upper_bound
months 127 133 1927 1933 I-upper_bound
after 134 139 1934 1939 O
the 140 143 1940 1943 O
last 144 148 1944 1948 O
dose 149 153 1949 1953 O
of 154 156 1954 1956 O
protocol 157 165 1957 1965 B-treatment
drug(s 166 172 1966 1972 I-treatment
) 172 173 1972 1973 I-treatment

Subjects 0 8 1974 1982 O
will 9 13 1983 1987 O
be 14 16 1988 1990 O
> 17 18 1991 1992 O
18 19 21 1993 1995 B-lower_bound
years 22 27 1996 2001 I-lower_bound
old 28 31 2002 2005 O

The 0 3 2006 2009 O
subject 4 11 2010 2017 O
has 12 15 2018 2021 O
a 16 17 2022 2023 O
baseline 18 26 2024 2032 B-clinical_variable
corrected 27 36 2033 2042 I-clinical_variable
QT 37 39 2043 2045 I-clinical_variable
interval 40 48 2046 2054 I-clinical_variable
( 49 50 2055 2056 I-clinical_variable
QTc 50 53 2056 2059 I-clinical_variable
) 53 54 2059 2060 I-clinical_variable
> 55 56 2061 2062 O
470 57 60 2063 2066 B-lower_bound
ms 61 63 2067 2069 I-lower_bound

The 0 3 2070 2073 O
subject 4 11 2074 2081 O
has 12 15 2082 2085 O
an 16 18 2086 2088 O
Eastern 19 26 2089 2096 B-clinical_variable
Cooperative 27 38 2097 2108 I-clinical_variable
Oncology 39 47 2109 2117 I-clinical_variable
Group 48 53 2118 2123 I-clinical_variable
( 54 55 2124 2125 I-clinical_variable
ECOG 55 59 2125 2129 I-clinical_variable
) 59 60 2129 2130 I-clinical_variable
performance 61 72 2131 2142 I-clinical_variable
status 73 79 2143 2149 I-clinical_variable
of 80 82 2150 2152 O
0 83 84 2153 2154 B-lower_bound
or 85 87 2155 2157 O
1 88 89 2158 2159 B-upper_bound

The 0 3 2160 2163 O
subject 4 11 2164 2171 O
has 12 15 2172 2175 O
disease 16 23 2176 2183 O
that 24 28 2184 2188 O
is 29 31 2189 2191 O
assessable 32 42 2192 2202 O
by 43 45 2203 2205 O
tumor 46 51 2206 2211 B-cancer
marker 52 58 2212 2218 I-cancer
, 58 59 2218 2219 O
physical 60 68 2220 2228 O
, 68 69 2228 2229 O
or 70 72 2230 2232 O
radiologic 73 83 2233 2243 O
means 84 89 2244 2249 O

The 0 3 2250 2253 O
subject 4 11 2254 2261 O
has 12 15 2262 2265 O
not 16 19 2266 2269 O
recovered 20 29 2270 2279 O
from 30 34 2280 2284 O
clinically 35 45 2285 2295 O
- 45 46 2295 2296 O
meaningful 46 56 2296 2306 O
toxicity 57 65 2307 2315 O
due 66 69 2316 2319 O
to 70 72 2320 2322 O
prior 73 78 2323 2328 B-treatment
therapy 79 86 2329 2336 I-treatment
( 87 88 2337 2338 O
i.e. 88 92 2338 2342 O
, 92 93 2342 2343 O
back 94 98 2344 2348 O
to 99 101 2349 2351 O
baseline 102 110 2352 2360 O
or 111 113 2361 2363 O
Grade 114 119 2364 2369 O
≤ 120 121 2370 2371 O
1 122 123 2372 2373 B-upper_bound
) 123 124 2373 2374 O

The 0 3 2375 2378 O
subject 4 11 2379 2386 O
has 12 15 2387 2390 O
received 16 24 2391 2399 O
any 25 28 2400 2403 O
other 29 34 2404 2409 O
type 35 39 2410 2414 O
of 40 42 2415 2417 O
investigational 43 58 2418 2433 B-treatment
agent 59 64 2434 2439 I-treatment
within 65 71 2440 2446 O
28 72 74 2447 2449 B-upper_bound
days 75 79 2450 2454 I-upper_bound
before 80 86 2455 2461 O
the 87 90 2462 2465 O
first 91 96 2466 2471 O
dose 97 101 2472 2476 O
of 102 104 2477 2479 O
study 105 110 2480 2485 O
treatment 111 120 2486 2495 B-treatment

The 0 3 2496 2499 O
subject 4 11 2500 2507 O
has 12 15 2508 2511 O
received 16 24 2512 2520 O
cytotoxic 25 34 2521 2530 B-treatment
chemotherapy 35 47 2531 2543 I-treatment
( 48 49 2544 2545 O
including 49 58 2545 2554 O
investigational 59 74 2555 2570 B-treatment
cytotoxic 75 84 2571 2580 I-treatment
chemotherapy 85 97 2581 2593 I-treatment
) 97 98 2593 2594 O
within 99 105 2595 2601 O
3 106 107 2602 2603 B-upper_bound
weeks 108 113 2604 2609 I-upper_bound
( 114 115 2610 2611 O
or 115 117 2611 2613 O
nitrosoureas 118 130 2614 2626 B-treatment
or 131 133 2627 2629 O
mitomycin 134 143 2630 2639 B-treatment
C 144 145 2640 2641 I-treatment
within 146 152 2642 2648 O
6 153 154 2649 2650 B-upper_bound
weeks 155 160 2651 2656 I-upper_bound
) 160 161 2656 2657 O
before 162 168 2658 2664 O
the 169 172 2665 2668 O
first 173 178 2669 2674 O
dose 179 183 2675 2679 O
of 184 186 2680 2682 O
PD 187 189 2683 2685 B-treatment
0332991 190 197 2686 2693 I-treatment

The 0 3 2694 2697 O
subject 4 11 2698 2705 O
is 12 14 2706 2708 O
known 15 20 2709 2714 O
to 21 23 2715 2717 O
be 24 26 2718 2720 O
positive 27 35 2721 2729 O
for 36 39 2730 2733 O
the 40 43 2734 2737 O
human 44 49 2738 2743 B-chronic_disease
immunodeficiency 50 66 2744 2760 I-chronic_disease
virus 67 72 2761 2766 I-chronic_disease
( 73 74 2767 2768 I-chronic_disease
HIV 74 77 2768 2771 I-chronic_disease
) 77 78 2771 2772 I-chronic_disease

The 0 3 2773 2776 O
subject 4 11 2777 2784 O
is 12 14 2785 2787 O
pregnant 15 23 2788 2796 B-pregnancy

diabetes 0 8 2797 2805 B-chronic_disease
mellitus 9 17 2806 2814 I-chronic_disease

hypertension 0 12 2815 2827 B-chronic_disease

ongoing 0 7 2828 2835 O
or 8 10 2836 2838 O
active 11 17 2839 2845 B-chronic_disease
infection 18 27 2846 2855 I-chronic_disease

symptomatic 0 11 2856 2867 O
congestive 12 22 2868 2878 B-chronic_disease
heart 23 28 2879 2884 I-chronic_disease
failure 29 36 2885 2892 I-chronic_disease
, 36 37 2892 2893 O
unstable 38 46 2894 2902 B-chronic_disease
angina 47 53 2903 2909 I-chronic_disease
pectoris 54 62 2910 2918 I-chronic_disease
, 62 63 2918 2919 O
stroke 64 70 2920 2926 B-chronic_disease
or 71 73 2927 2929 O
myocardial 74 84 2930 2940 B-chronic_disease
infarction 85 95 2941 2951 I-chronic_disease
within 96 102 2952 2958 O
3 103 104 2959 2960 B-upper_bound
months 105 111 2961 2967 I-upper_bound

